Selling seems to have come to an end from the seller. however it is anyone's guess. my observations as well. 'will we look back at this price as a buying opportunity' I would have to say 100% yes. there is no reason for the sp to be where it is other than someone with a larger holding than market demand pushing the sp where it is today. sentiment - the company is in the strongest most advanced position it has ever been. Nanabis trial is only a few months off completion. FDA lodging end of 2018 (Canada and US) not to mention Medlab's 100% owned Subsidiary based in California (http://inmedtech.co/). Places the company in a nice position once things get moving with Nanabis and Nanabidal once FDA approval is announced. And this is only underlining the cannabis based part of the company.... the Nutraceutical side of things is yet to blossom too. But I imagine once Medlab's range gets more awareness the stars will align SP is a lot higher than today. And more than likely paying dividend to shareholders when profits start rolling in. The health space Medlab is targeting is huge and varies dramatically from chronic disease to the next. The company has announced twice now since November 2017 that they expect bullish revenue in the next 18-24 months (from November 2017).
Not too worried where the SP is now. When comparing this company to all the others... MDC has put in the harder yards, earns the most revenue than any MM on the ASX and has a broader market reach. So its quite simple to see (for me) which is the safest bet in the MM field.
Add to My Watchlist
What is My Watchlist?
